RESULTS FROM TWO PHASE 3 RANDOMIZED TRIALS OF ENOBOSARM, SELECTIVE ANDROGEN RECEPTOR MODULATOR (SARM), FOR THE PREVENTION AND TREATMENT OF MUSCLE WASTING IN NSCLC.

被引：0
|
作者：
Crawford, Jeffrey [1 ]
Prado, Carla M. M. [2 ]
Hancock, Michael L. [3 ]
Johnston, Mary A. [3 ]
Dalton, James T. [3 ]
Steiner, Mitchell S. [3 ]
机构：
[1] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA
[2] Florida State Univ, Tallahassee, FL 32306 USA
[3] Gtx Inc, Memphis, TN USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
muscle wasting; cachexia; NSCLC; enobosarm;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-026
引用
收藏
页码：S1199 / S1199
页数：1
相关论文
共 50 条
  • [1] Results from two Phase 3 randomized trials of enobosarm, selective androgen receptor modulator (SARM), for the prevention and treatment of muscie wasting in NSCLC
    Crawford, J.
    Dalton, J. T.
    Hancock, M. L.
    Johnston, M. A.
    Steiner, M. S.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S10 - S10
  • [2] EFFECT OF ENOBOSARM, A SELECTIVE ANDROGEN RECEPTOR MODULATOR, ON PHYSICAL FUNCTION IN NSCLC PATIENTS WITH MUSCLE WASTING
    Dodson, S.
    Hancock, M.
    Johnston, M. A.
    Steiner, M.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (06) : S69 - S69
  • [3] Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)
    Crawford, Jeffrey
    Prado, Carla M. M.
    Johnston, Mary Ann
    Gralla, Richard J.
    Taylor, Ryan P.
    Hancock, Michael L.
    Dalton, James T.
    CURRENT ONCOLOGY REPORTS, 2016, 18 (06)
  • [4] Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)
    Jeffrey Crawford
    Carla M. M. Prado
    Mary Ann Johnston
    Richard J. Gralla
    Ryan P. Taylor
    Michael L. Hancock
    James T. Dalton
    Current Oncology Reports, 2016, 18
  • [5] Baseline characteristics from two ongoing phase III trials for the prevention and treatment of muscle wasting in NSCLC.
    Steiner, Mitchell S.
    Gralla, Richard J.
    Prado, Carla M. M.
    Hancock, Michael L.
    Dalton, James T.
    Johnston, Mary Ann
    Crawford, Jeffrey
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Discovery of GSK2881078A: A selective androgen receptor modulator (SARM) for the treatment of muscle wasting disorders
    Turnbull, Philip
    Cadilla, Rodolfo
    Shen, Ying
    Poole, Chuck
    Stewart, Eugene
    Gampe, Robert
    Clark, Richard
    Henke, Brad
    Russell, Alan
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 249
  • [7] IS SARM - Selective Androgen Receptor Modulator: A Chance for Therapeutic Approach in Muscle-Wasting Chronic Conditions?
    Bartoli, Alessandro
    Maffulli, Nicola
    Oliva, Gabriella
    Ziello, Salvatore
    Oliva, Francesco
    MLTJ-MUSCLES LIGAMENTS AND TENDONS JOURNAL, 2024, 14 (02): : 361 - 366
  • [8] Selective androgen receptor modulators for the prevention and treatment of muscle wasting associated with cancer
    Dalton, James T.
    Taylor, Ryan P.
    Mohler, Michael L.
    Steiner, Mitchell S.
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2013, 7 (04) : 345 - 351
  • [9] Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials
    Fonseca, Guilherme Wesley Peixoto Da
    Dworatzek, Elke
    Ebner, Nicole
    Von Haehling, Stephan
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (08) : 881 - 891
  • [10] Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER plus /AR plus breast cancer - final results from an international Phase 2 randomized study
    Palmieri, Carlo
    Linden, Hannah
    Birrell, Stephen
    Lim, Elgene
    Schwartzberg, Lee S.
    Rugo, Hope S.
    Cobb, Patrick
    Jain, Kirti
    Vogel, Charles
    O'Shaughnessy, Joyce A.
    Getzenberg, Robert H.
    Steiner, Mitchell S.
    Brufsky, Adam
    Overmoyer, Beth
    CANCER RESEARCH, 2021, 81 (04)
12345